Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma

被引：2
|
作者：
Agarwala, Sanjiv S. [1 ,2 ]
Gray, Robert J. [3 ,4 ]
Wong, Michael K. K. [5 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] St Lukes Canc Ctr, Bethlehem, PA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Boston, MA 02115 USA
[5] GU Clin Roswell Pk Canc Inst, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 25期
关键词：
ADJUVANT THERAPY; TRIAL;
D O I：
10.1200/JCO.2009.23.0334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [1] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma Reply
    Pectasides, Dimitrios
    Dafni, Urania
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E84 - E84
  • [2] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    CANCER JOURNAL, 2000, 6 (03): : 139 - 145
  • [3] Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Weichenthal, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : E70 - E70
  • [4] Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma Reply
    Pectasides, Dimitrios
    Dafni, Urania
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : E71 - E71
  • [5] Acute rhabdomyolysis associated with administration of high-dose interferon alfa-2b for high-risk melanoma
    Ramirez, A. Vanegas
    Fischer, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 50 - 50
  • [6] Adjuvant interferon alfa-2b for high-risk melanoma
    Retsas, S
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1968 - 1968
  • [7] Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b
    Fluck, M
    Kamanabrou, D
    Lippold, A
    Reitz, M
    Atzpodien, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (03) : 280 - 289
  • [8] Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma
    Levesque, N.
    Mitchinson, K.
    Lawrie, D.
    Fedorak, L.
    MacDonald, D.
    Normand, C.
    Pouliot, J. F.
    CURRENT ONCOLOGY, 2008, 15 (01) : 36 - 41
  • [9] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma
    Mitchell, Malcolm S.
    Abrams, Judith
    Thompson, John A.
    Kashani-Sabet, Mohammed
    DeConti, Ronald C.
    Hwu, Wen-Jen
    Atkins, Michael B.
    Whitman, Eric
    Ernstoff, Marc S.
    Haluska, Frank G.
    Jakowatz, James G.
    Das Gupta, Tapas K.
    Richards, Jon M.
    Samlowski, Wolfram E.
    Costanzi, John J.
    Aronson, Frederick R.
    Deisseroth, Albert B.
    Dudek, Arkadiusz Z.
    Jones, Vicky E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2078 - 2085
  • [10] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
12345